Nuvation Bio Inc (NUVB)

Official site

HEALTHCARE • BIOTECHNOLOGY • NYSE

$4.74

+0.06 (+1.28%)

Market Cap: $1.64B

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

70%(16/23)

Avg Surprise

-149.60%

Streak

2 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.09

Range$-0.09 - $-0.09

2 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate DriftChange to current

90d ago$-0.11+18.2%

60d ago$-0.11+18.2%

30d ago$-0.11+18.2%

7d ago$-0.11+18.2%

Current$-0.09

Revenue Consensus

$35M

Range$28M - $40M

13 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.13

Range$-0.13 - $-0.13

2 analysts

Revenue Consensus

$71M

Range$51M - $96M

13 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.13	$-0.13 - $-0.13	-	-	2	-	-
Sep 30, 2026Sep 26EST	-	$-0.09	$-0.09 - $-0.09	-	-	2	0 1 30d	-
Jun 30, 2026Jun 26 Reported Aug 6, 2026Reported Aug 6	$-0.15	$-0.15	$-0.15 - $-0.15	+0.00%	Beat	1	0 1 30d	+11.8%
Mar 31, 2026Mar 26 Reported May 4, 2026Reported May 4	$0.01	N/A	-	+123.15%	Beat	1	No revisions (30d)	+107.7%
Dec 31, 2025Dec 25 Reported Mar 2, 2026Reported Mar 2	$-0.11	$-0.09	$-0.10 - $-0.08	-22.22%	Miss	2	No revisions (30d)	+5.6%
Sep 30, 2025Sep 25 Reported Nov 3, 2025Reported Nov 3	$-0.16	$-0.17	$-0.17 - $-0.17	+5.88%	Beat	1	No revisions (30d)	-33.3%
Jun 30, 2025Jun 25 Reported Aug 7, 2025Reported Aug 7	$-0.17	$-0.17	$-0.17 - $-0.17	+0.00%	Beat	1	0 1 30d	+90.8%
Mar 31, 2025Mar 25 Reported May 7, 2025Reported May 7	$-0.13	$-0.12	$-0.13 - $-0.11	-8.33%	Miss	2	No revisions (30d)	-225.0%
Dec 31, 2024Dec 24 Reported Mar 6, 2025Reported Mar 6	$-0.12	$-0.12	$-0.14 - $-0.10	+2.92%	Beat	2	1 0 30d	-94.2%
Sep 30, 2024Sep 24 Reported Nov 6, 2024Reported Nov 6	$-0.12	$-0.10	$-0.18 - $-0.08	-20.00%	Miss	5	1 0 30d	-100.0%
Jun 30, 2024Jun 24 Reported Aug 5, 2024Reported Aug 5	$-1.85	$-0.05	$-0.07 - $-0.05	-3600.00%	Miss	6	No revisions (30d)	-2542.9%
Mar 31, 2024Mar 24 Reported May 14, 2024Reported May 14	$-0.04	$-0.05	-	+20.00%	Beat	5	No revisions (30d)	+50.0%
Dec 31, 2023Dec 23 Reported Feb 29, 2024Reported Feb 29	$-0.06	$-0.10	$-0.13 - $-0.09	+40.00%	Beat	6	No revisions (30d)	+40.0%
Sep 30, 2023Sep 23 Reported Nov 2, 2023Reported Nov 2	$-0.06	$-0.08	$-0.10 - $-0.07	+25.00%	Beat	6	No revisions (30d)	+45.5%
Jun 30, 2023Jun 23 Reported Aug 3, 2023Reported Aug 3	$-0.07	$-0.08	$-0.10 - $-0.07	+12.50%	Beat	6	No revisions (30d)	+50.0%
Mar 31, 2023Mar 23 Reported May 4, 2023Reported May 4	$-0.08	$-0.06	$-0.08 - $-0.03	-33.33%	Miss	6	No revisions (30d)	+0.0%
Dec 31, 2022Dec 22 Reported Mar 15, 2023Reported Mar 15	$-0.10	$-0.11	$-0.14 - $-0.08	+9.09%	Beat	6	No revisions (30d)	+16.7%
Sep 30, 2022Sep 22 Reported Nov 3, 2022Reported Nov 3	$-0.11	$-0.15	$-0.17 - $-0.11	+26.67%	Beat	7	No revisions (30d)	-22.2%
Jun 30, 2022Jun 22 Reported Aug 4, 2022Reported Aug 4	$-0.14	$-0.11	$-0.13 - $-0.10	-27.27%	Miss	6	No revisions (30d)	-75.0%
Mar 31, 2022Mar 22 Reported May 9, 2022Reported May 9	$-0.08	$-0.13	$-0.14 - $-0.13	+38.46%	Beat	5	No revisions (30d)	+27.3%
Dec 31, 2021Dec 21 Reported Feb 28, 2022Reported Feb 28	$-0.12	$-0.12	$-0.13 - $-0.11	+0.00%	Beat	6	No revisions (30d)	-200.0%
Sep 30, 2021Sep 21 Reported Nov 10, 2021Reported Nov 10	$-0.09	$-0.10	$-0.12 - $-0.10	+10.00%	Beat	5	No revisions (30d)	-125.0%
Jun 30, 2021Jun 21 Reported Aug 12, 2021Reported Aug 12	$-0.08	$-0.10	$-0.12 - $-0.08	+20.00%	Beat	5	No revisions (30d)	-
Mar 31, 2021Mar 21 Reported May 17, 2021Reported May 17	$-0.11	$-0.06	$-0.10 - $-0.05	-83.33%	Miss	6	No revisions (30d)	-
Dec 31, 2020Dec 20 Reported Jan 20, 2021Reported Jan 20	$-0.04	$-0.05	$-0.06 - $-0.04	+20.00%	Beat	3	No revisions (30d)	-
Sep 30, 2020Sep 20 Reported Nov 16, 2020Reported Nov 16	$-0.04	N/A	-	N/A	Beat	-	-	-
Jun 30, 2020Jun 20 Reported Aug 14, 2020Reported Aug 14	$0.00	$0.00	-	N/A	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-11.56	EV/EBITDA	N/A
Price/FCF	-12.82x	FCF Yield	-7.80%
Profitability
Profit Margin	-88.20%	Operating Margin	-161.10%
ROE	-47.80%	ROIC	-21.19%
Financial Health
Debt/Equity	0.98x	Interest Coverage	-3.73x
Current Ratio	8.37x	Quick Ratio	8.14x
Trading Statistics
Beta	1.62	Avg Volume	5.39M
52-Week High	$9.75	52-Week Low	$3.36

Technical Indicators Dashboard

Moving Averages

SMA 10$4.88

SMA 20$5.32

SMA 50$6.05

SMA 200$5.58

EMA 10$4.95

EMA 20$5.26

EMA 50$5.70

EMA 200$5.48

MACD

Line: -0.39Signal: -0.36Hist: -0.03

ADX

ADX: 34.2+DI: 12.6-DI: 36.0

Aroon & PSAR

Aroon UpN/A

Aroon Down96.0

PSAR$4.87

Bollinger Bands

Upper Band$6.28

Lower Band$4.36

%B Position3597%(Upper)

Band Width0.20

RSI (14-Day)

Oversold

28.4

Momentum Oscillators

Stoch %K8.1

Stoch %D11.9

Williams %R-89.3

ROC (10d)-14.7%

Momentum-0.82

CCI (20d)-88.5

MFI (14d)26.1

Volatility Measures

ATR (14d)$0.26(5.6%)

StdDev (20d)0.48

Hist Vol43.7%(High)

Volume Flow

VWAP$4.75

OBV57.4M

AD Line46.5M

CMF (20d)-0.184

Volume Metrics

Avg Vol (20d)5.5M

Vol Ratio0.9x

VWMA (20d)$5.23

Pivot Points

R3$4.97

R2$4.89

R1$4.78

Pivot Point$4.70

S1$4.59

S2$4.51

S3$4.40

Advanced Oscillators

TSI-40.51

Ultimate Osc45.4

KST-211.31

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$31.69M	$83.23M	$41.87M	$13.12M	$4.83M	$3.08M	$-2,162,000	$727,000	$1.44M	$0	$264,000	$0
Cost of Revenue	$0	$0	$-8,019,000	$3.35M	$0	$0	$-2,862,000	$1.51M	$1.35M	$0	$55,000	$0
Gross Profit	$31.69M	$83.23M	$49.88M	$9.77M	$4.83M	$3.08M	$700,000	$-788,000	$88,000	$0	$209,000	$0

Operating Expenses	$82.72M	$79.35M	$83.92M	$66.20M	$68.42M	$62.09M	$62.52M	$47.31M	$470.47M	$20.20M	$20.83M	$26.34M
R&D	$30.66M	$35.05M	$34.30M	$28.85M	$27.36M	$24.60M	$29.30M	$27.73M	$454.32M	$12.84M	$15.35M	$18.56M
SG&A	$43.50M	$38.68M	$41.18M	$37.36M	$38.66M	$35.39M	$26.14M	$19.58M	$16.16M	$7.36M	$5.48M	$7.78M
Operating Income	$-51,036,000	$3.88M	$-34,037,000	$-56,434,000	$-63,589,000	$-59,004,000	$-53,942,000	$-48,101,000	$-470,385,000	$-20,199,000	$-20,831,000	$-26,339,000

Interest Income	$4.60M	$5.11M	$5.30M	$6.03M	$4.78M	$5.32M	$6.06M	$6.73M	$7.14M	$7.13M	$6.93M	$6.52M
Interest Expense	$16.23M	$6.71M	$6.67M	$6.53M	$421,000	$54,000	$89,000	$120,000	$132,000	$0	$0	$0
Income Before Tax	$-62,840,000	$5.40M	$-36,592,000	$-55,792,000	$-59,007,000	$-53,236,000	$-49,445,000	$-41,210,000	$-462,492,000	$-14,792,000	$-13,787,000	$-19,649,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-62,840,000	$5.40M	$-36,592,000	$-55,792,000	$-59,007,000	$-53,236,000	$-49,445,000	$-41,210,000	$-462,492,000	$-14,792,000	$-13,787,000	$-19,649,000

EBITDA	$-51,039,000	$7.01M	$-35,535,000	$-55,727,000	$-64,326,000	$-59,670,000	$-56,858,000	$-49,745,000	$-471,677,000	$-24,685,000	$-24,058,000	$-29,559,000
EBIT	$-51,214,000	$6.99M	$-35,213,000	$-55,291,000	$-63,365,000	$-58,506,000	$-55,423,000	$-47,805,000	$-469,497,000	$-21,923,000	$-20,854,000	$-26,184,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about NUVB

News

Nuvation Bio (NUVB) CSO sells 100K shares at $7.09

Nuvation Bio Inc.'s Chief Scientific Officer, Gary Hattersley, exercised options for 100,000 shares of Class A Common Stock at $1.87 per share and subsequently sold all 100,000 shares at a weighted-average price...

Stock Titan•Aug 21, 2026 5:12 PM ET8/21/26•Somewhat-Bearish

Nuvation Bio (NYSE: NUVB) posts $31.7M Q2 revenue and $62.8M loss

Nuvation Bio (NYSE: NUVB) announced Q2 2026 revenue of $31.7 million, driven by strong sales of its ROS1 inhibitor IBTROZI and collaboration agreements...

Stock Titan•Aug 6, 2026 7:09 AM ET8/6/26•Neutral

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

Zacks Commentary•Aug 3, 2026 10:34 AM ET8/3/26•Neutral

Nuvation Bio Inc. ( NUVB ) Expected to Beat Earnings Estimates: Should You Buy?

Nuvation Bio (NUVB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Commentary•Jul 30, 2026 10:00 AM ET7/30/26•Somewhat-Bullish

Nuvation Bio (NUVB) Corporate presentation Summary

Nuvation Bio (NUVB) presented a corporate summary highlighting its focus on oncology medicines and strong financial position. The company emphasized the success of IBTROZI (taletrectinib)...

Quartr•Jul 20, 2026 11:40 AM ET7/20/26•Bullish

NUVB Valuation and Fair Value

P/E: -11.6x
P/FCF: -12.8x
P/B: 6.5x

See GNG's fair value

NUVB Profitability: Margins, ROIC and FCF

Gross margin: 102.7%
Operating margin: -161.1%
Net margin: -88.2%
ROIC: -21.2%
ROE: -47.8%
FCF margin: -75.9%
FCF yield: -7.8%

NUVB Competitors

Company	Ticker
Biohaven Ltd.	BHVN
Omnicell Inc	OMCL
Azenta Inc	AZTA
Forte Biosciences Inc	FBRX
Novocure Ltd	NVCR
Zenas BioPharma, Inc. Common Stock	ZBIO
Intellia Therapeutics Inc	NTLA
Kestra Medical Technologies, Ltd. Common Stock	KMTS

Sector: Healthcare

NUVB Analyst Ratings

Consensus: Buy
Analysts: 13
Strong Buy: 3
Buy: 9
Hold: 1
Sell: 0
Strong Sell: 0

NUVB Bull Case vs Bear Case

Bull case

NUVB grew quarterly revenue 556.0% year over year.
92.3% of NUVB's analyst ratings are Buy or Strong Buy.

Bear case

NUVB has a -88.2% net profit margin.
NUVB beat EPS estimates in 37.5% of its last 8 reported quarters.

NUVB Earnings: Beat Rate and Next Report

Beat rate: 3 of 8 quarters (37.5%)
Average surprise: 10.2%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.09
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 0 up, 1 down

Frequently Asked Questions About NUVB

Does NUVB pay dividends?

Nuvation Bio Inc (NUVB) does not currently pay a regular dividend.

What is NUVB's market cap?

Nuvation Bio Inc (NUVB) has a market capitalization of $1.64B with a current stock price of $4.74.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In